At the November 2024 meeting, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorisation under exceptional circumstances for InflaRx’s Gohibic® (vilobelimab) for treatment of adults with SARS-CoV2-induced acute respiratory distress syndrome (ARDS) who are receiving systemic corticosteroids. A marketing authorisation under exceptional circumstances is recommended when the benefit/risk assessment is positive but where the rarity of the disease means it is unlikely that comprehensive data can be obtained under normal conditions of use.
The CHMP also recommended the following indication extensions:
- MSD’s Keytruda® (pembrolizumab), in combination with pemetrexed and platinum chemotherapy for first-line treatment of adults with unresectable non-epithelioid malignant pleural mesothelioma;
- BMS’ Opdivo® (nivolumab) and Yervoy® (ipilimumab), in combination, for mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer in first-line treatment of unresectable or metastatic colorectal cancer or for treatment of metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy;
- Janssen’s Rybrevant® (amivantamab), in combination with lazertinib, for first-line treatment of adult patients with advanced NSCLC with EGFR Exon 19 deletions or Exon 21 l858R substitution mutations;
- Sanofi’s Kevzara® (sarilumab), in a new strength (175mg/ml solution for injection in vial), for active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older, who have responded inadequately to previous therapy with conventional synthetic DMARDs, as monotherapy or in combination with MTX; and Sarclisa® (isatuximab), in combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant;
- Regeneron/Ultragenyx’s Evkeeza® (evinacumab) as an adjunct to diet and other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and paediatric patients aged 6 months and older with homozygous familial hypercholesterolaemia.
Four biosimilars also received positive opinions at CHMP’s November meeting; two Samsung Bioepis denosumab biosimilars (reported here) and two aflibercept biosimilars for Formycon/Klinge (reported here).
In addition, the CHMP adopted a positive opinion for Eisai’s Leqembi® (lecanemab), as reported here.